(Q45309210)

English

Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lun

scientific article

Statements

Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lun (English)
David H Johnson
Eric Mininberg
David P Carbone
Ted Henderson
Edward S Kim
Jack J Lee
Diane D Liu
Mylene T Truong
Waun K Hong
Hai Tran
Anne Tsao
Dong Xie
David A Ramies
Robert Mass
Somasekar Seshagiri
David A Eberhard
Sean K Kelley
Alan Sandler
7 March 2005
2544-2555

Identifiers

 
edit
    edit
      edit
        edit
          edit
            edit
              edit
                edit
                  edit